Novel Lysine-Based Thioureas as Mechanism-Based Inhibitors of Sirtuin 2 (SIRT2) with Anticancer Activity in a Colorectal Cancer Murine Model.
暂无分享,去创建一个
Hening Lin | Xuan Lu | Qingjie Zhao | Ji Cao | Qingjie Zhao | Hening Lin | I. Price | Tatsiana Kosciuk | Jun Young Hong | Ji Cao | Min Yang | J. Hong | Ali Sohail Farooqi | Ian Robert Price | Jessica Jingyi Bai | Ali S. Farooqi | Tatsiana Kosciuk | Min Yang | J. Bai | Xuan Lu
[1] J. Denu,et al. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. , 2003, Molecular cell.
[2] Johan Auwerx,et al. Sirtuins as regulators of metabolism and healthspan , 2012, Nature Reviews Molecular Cell Biology.
[3] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[4] R. Weinberg,et al. hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase , 2001, Cell.
[5] P. Giannakakou,et al. A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity. , 2016, Cancer cell.
[6] X. Wang,et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. , 2011, Cancer cell.
[7] Wolfgang Sippl,et al. Selective Sirt2 inhibition by ligand-induced rearrangement of the active site , 2015, Nature Communications.
[8] Andrew H. Beck,et al. The SIRT2 Deacetylase Stabilizes Slug to Control Malignancy of Basal-like Breast Cancer. , 2016, Cell reports.
[9] Lee Baker,et al. Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator , 2007, Cancer cell.
[10] A. Sauve,et al. Transition state of ADP-ribosylation of acetyllysine catalyzed by Archaeoglobus fulgidus Sir2 determined by kinetic isotope effects and computational approaches. , 2010, Journal of the American Chemical Society.
[11] L. Guarente,et al. SIRT1 and other sirtuins in metabolism , 2014, Trends in Endocrinology & Metabolism.
[12] David Sinclair,et al. Sirtuins in mammals: insights into their biological function. , 2007, The Biochemical journal.
[13] L. Guarente,et al. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase , 2000, Nature.
[14] Xiaopeng Li,et al. A mechanism-based potent sirtuin inhibitor containing Nε-thiocarbamoyl-lysine (TuAcK). , 2011, Bioorganic & medicinal chemistry letters.
[15] J. Marshall,et al. Molecularly Targeted Therapy for Metastatic Colon Cancer: Proven Treatments and Promising New Agents , 2010, Gastrointestinal cancer research : GCR.
[16] M. Raponi,et al. KRAS mutations predict response to EGFR inhibitors. , 2008, Current opinion in pharmacology.
[17] Hening Lin,et al. The Substrate Specificity of Sirtuins. , 2016, Annual review of biochemistry.
[18] Q. Hao,et al. Efficient Demyristoylase Activity of SIRT2 Revealed by Kinetic and Structural Studies , 2015, Scientific Reports.
[19] C. Wolberger,et al. Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme. , 2005, Molecular cell.
[20] K. Haigis,et al. HDAC6 and SIRT2 Regulate the Acetylation State and Oncogenic Activity of Mutant K-RAS , 2013, Molecular Cancer Research.
[21] J. O’Sullivan,et al. Current targeted therapies in the treatment of advanced colorectal cancer: a review , 2016, Therapeutic advances in medical oncology.
[22] Y. Surh,et al. Janus-faced role of SIRT1 in tumorigenesis , 2012, Annals of the New York Academy of Sciences.
[23] E. Knoll,et al. Mechanism of Inhibition of the Human Sirtuin Enzyme SIRT3 by Nicotinamide: Computational and Experimental Studies , 2014, PloS one.
[24] A. Biankin,et al. The histone deacetylase SIRT2 stabilizes Myc oncoproteins , 2012, Cell Death and Differentiation.
[25] P. Distefano,et al. Inhibition of SIRT1 Catalytic Activity Increases p53 Acetylation but Does Not Alter Cell Survival following DNA Damage , 2006, Molecular and Cellular Biology.
[26] Paola Chiarugi,et al. Anoikis molecular pathways and its role in cancer progression. , 2013, Biochimica et biophysica acta.
[27] M. Fraga,et al. Role of sirtuins in stem cell differentiation. , 2013, Genes & cancer.
[28] Ruben Abagyan,et al. Sirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's Disease , 2007, Science.
[29] Ji Cao,et al. Direct Comparison of SIRT2 Inhibitors: Potency, Specificity, Activity‐Dependent Inhibition, and On‐Target Anticancer Activities , 2018, ChemMedChem.
[30] Peter Fristrup,et al. Investigating the Sensitivity of NAD+-dependent Sirtuin Deacylation Activities to NADH* , 2016, The Journal of Biological Chemistry.
[31] A. Lièvre,et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] C. Yeh,et al. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients , 2016, Oncotarget.
[33] X. Niu,et al. Desuccinylation of pyruvate kinase M2 by SIRT5 contributes to antioxidant response and tumor growth , 2016, Oncotarget.
[34] Q. Hao,et al. Deacylation Mechanism by SIRT2 Revealed in the 1'-SH-2'-O-Myristoyl Intermediate Structure. , 2017, Cell chemical biology.
[35] M. Weyand,et al. Ex-527 inhibits Sirtuins by exploiting their unique NAD+-dependent deacetylation mechanism , 2013, Proceedings of the National Academy of Sciences.
[36] I. Shin,et al. A potent and selective small molecule inhibitor of sirtuin 1 promotes differentiation of pluripotent P19 cells into functional neurons , 2016, Scientific Reports.